Suppose they gave a revolution and nobody came? We're meant to be in the midst of a revolution in life sciences publishing but, for a revolution, it's awfully quiet. For the moment at least, the ancien régime -in the form of traditional peer review and conventional commercial journals -seems to be winning. The latest fusillade came from Stanford University's HighWire Press, which has just begun offering free online access to back issues of dozens of journals.
The revolution was started early last year by Harold Varmus, then director of the National Institutes of Health. Urged on by those who wanted a freely accessible central online repository for biology papers and data, and who were also fed up with the staggering cost of journals and the vagaries of peer review, Varmus threw NIH's weight behind a brand new idea. The plan was to develop a free online 'e-print' archive where life scientists could post papers without having to go through peer review.
The idea may have been brand new to biologists but it was modeled on a highly successful preprint archive in physics and related fields, housed at Los Alamos National Laboratory in New Mexico since 1991. Scientists post draft papers there, then hunker down to endure trenchant analysis and the occasional catcall in the very public peer review by their fellows.
The Los Alamos e-print archive seems to work really well -so much so that it has been expanded to include papers in mathematics, computer science, and "non-linear science", whatever that is. Papers are 'published' with no lag time at all, revised on the basis of the posted criticisms, and republished quickly. By all accounts, the quality of the papers is good. Perhaps even more important, the archive is a perpetual scientific meeting without the jet lag, a constantly changing, often fruitful online dialog among members of a worldwide community of scientists. In short, it has been good for scientists and for science.
So, Varmus and his colleagues reasoned, why not an analagous e-print archive for biology, free and open to all? They were quickly told why not. First, biologists seem to have faith in peer review. They concede its imperfections and its occasional evils, but seem to believe it is a bulwark against junk science. (Not to mention much better for promotion prospects than publishing unreviewed papers.) Second, a free archive is a mortal threat to commercial publishers and to scientific societies that depend on journals for income.
Why is a free and open publishing system bombing with life scientists?
By last summer, the e-print archive had become a footnote to the NIH plan. From then on, the focus was not only on reviewed papers, it was on existing journals, and then on back issues of existing journals. So far, scientists have expressed no interest whatever in the still-hypothetical PubMed Express. Massive lack of excitement has also attended a couple of other attempts at establishing a home for unreviewed papers in the life sciences, both sponsored by major UK medical journals.
The Lancet has put up what it calls an e-print server, but the site's content is exclusively papers that have been or are being considered by that journal (including a few that have been rejected). The Lancet established its electronic research archive in international health last summer, to address neglect of "the effects of electronic publishing on research and communication in the developing world." Doctors there need affordable access to medical information, the Lancet said, and attention should be paid to the often-forgotten contributions of researchers there.
After the announcement was published, the Lancet's John McConnell held his breath, awaiting the flood of submissions. It hasn't come. "We've had them trickle in," he says. "I feared we wouldn't have the resources to handle them, but that has not proved to be true." At this writing, the archive contained just seven papers.
The story is the same at the British Medical Journal. It launched Netprints in December as "a place for authors to archive their completed studies -before, during, or after peer review by other agencies. Its scope is original research into clinical medicine and health." At this writing, Netprints contained nine papers.
Why is a free and open publishing system that seems to work brilliantly in physics and mathematics bombing with life scientists? McConnell suggests that the Lancet's problem may be lack of publicity; unless you read the journal, you probably wouldn't know that its international health archive existed. But he offers that exculpation with a palpable lack of conviction. The truth is, he says, that he's now more pessimistic than optimistic about e-publishing.
The European Molecular Biology Organization (EMBO) is planning E-Biosci, a journal archive, for late this year. It will be somewhat similar to HighWire, offering some free back issues of journals and links to papers in current journals that will, in most cases, require a paid subscription.
Everything on E-Biosci will be peer-reviewed. Frank Gannon, EMBO's executive director, thinks life scientists are comforted by the imprimatur of peer review, and for good reason.
There's far more possibility of mischief in biology than in physics, he says. Unreviewed papers could send out quasi-scientific messages on the basis of badly done studies, and the press might pick them up. An association with EMBO could confer respectability on junk science. Gannon reports that EMBO's advisers are also concerned about politically driven papers -which might argue, for example, that all genetically modified organisms are bad. Another risk is slanted reports on new products, especially new drugs. "These things are hard to work through even with peer review," he points out. "We felt it was wiser to ensure that at least somebody reads a paper carefully."
John McConnell concedes that junk is a risk and that's why there's a preliminary screening process at the Lancet's e-print archive. "The quality of our stuff has been reasonably good," he reports. "We haven't yet had problems with papers that are mad, bad, or dangerous." The BMJ deals with the junk issue by posting a stern disclaimer in large type on its archive's opening page: "Warning! Articles posted on this site have not yet been accepted for publication by a peer reviewed journal. They are presented here mainly for the benefit of fellow researchers. Casual readers should not act on their findings, and journalists should be wary of reporting them."
Beneath all the palaver about peer review lurks the mighty iceberg of the journal-publishing industry. 
Who's doing what in biomedical e-publishing
Commercial publishers (such as Elsevier Science, which owns Current Biology, and the Lancet) are large and profitable -unhappy librarians say outrageously profitable -and understandably not delighted at the thought of competitors that are universally accessible and free. Many scientific societies believe they would perish if people fancied free e-prints instead of their journals, which serve as magnets -often the only magnets -for members and income. They may be right.
There's far more possibility of mischief in biology than in physics
Gannon, for one, says he is more worried about the survival of scientific societies than of commercial publishers, although many of the latter are advising EMBO's project. We've ended up with the present system of commercial publishers because they do it efficiently -and because capitalism rules, he argues. But he hopes an increasing amount of material will be offered free as the societies -and perhaps commercial publishers as well -become comfortable with reducing the amount of delay between an issue's publication date and the time it becomes available gratis.
John McConnell points out that it is really too early to say whether unreviewed e-prints will ever catch on in the life sciences. The concept may become more acceptable, he says, as people learn about it and do it, and if some sponsor is willing to hang in there for a long time waiting for it to work. It is clear he is no longer holding his breath.
For now at least, events on the barricades of the life sciences publishing revolution suggest that the Jacobins have yet to make their mark.
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Gazetteer The Cancer Research Campaign
What is it famous for? The Cancer Research Campaign (CRC) is one of two rival charities that dominate cancer research funding in the UK -the other being the Imperial Cancer Research Fund (ICRF). But most British people are probably more aware of the CRC's charity shops, which are on almost every high street.
How did it begin?
In 1923, a group of clinicians, who felt that the work of the ICRF had reached a "dried up condition of stagnation", founded the British Empire Cancer Campaign for Research, the forerunner to the CRC. According to Sir Walter Morley Fletcher -who, in his capacity as first secretary of the Medical Research Council, co-ordinated all British medical research at the time -the founders of the CRC showed "almost avowed rivalry, not untinged by hostility" to the ICRF. This rivalry continues to this day, albeit less overtly.
Does it have much money to give away?
The CRC spent £56 million (US$89 million) on research in 1999. Compare this with the £23 million spent by the UK government on cancer research last year.
Where does the money come from?
About 87% of its £69 million income in 1999 came from legacies and donations. The CRC's chain of charity shops raised £4 million. The charity has also become more inventive with its fundraising in the past couple of years. Through a partnership with the International Star Registry, anyone can name a star in the constellation of Cancer, in return for a small contribution to the CRC. The charity has also entered into endorsement partnerships with the likes of Kellogg's, the breakfast cereal makers. It remains to be seen whether the amount of effort devoted by the CRC to getting publicity for the partnerships will be justified by the returns.
Where is it based? The charity's fundraising and media relations machinery, and its grant administrators, are based in its headquarters in central London. The CRC's one-stop cancer information service -staffed by biomedical professionals -is also based there.
What's it like to work there? Well, whether or not it makes a difference to the atmosphere there, men are very much in the minority. Although the present Director General of the CRC (Gordon McVie) is male, women make up 88% of the 825 staff at headquarters. TV crews and reporters seem to be ever-present, eager for the scoop on the next cancer 'breakthrough', and there's usually a pleasant bustle of activity -but this shifts up several gears whenever the ICRF receives one column inch of publicity more than the CRC.
Does the CRC have its own labs?
No. Unlike the ICRF, which directly employs scientists at its own labs, the CRC provides funding purely through research grants, although it does also provide personal support in the form of fellowships and studentships. This allows it the flexibility to support scientists no matter where they are based (within the UK), and it avoids expensive overheads for bricks and mortar.
Has it funded any well-known work?
Yes. David Lane, co-discoverer of the p53 tumour suppressor, and Mike Stratton, whose team identified and cloned the breast cancer susceptibility gene BRCA2, are two of the 1,300 scientists funded by the CRC.
